Hypera S.A. (OTCMKTS:HYPMY) Short Interest Down 99.1% in March

Hypera S.A. (OTCMKTS:HYPMY - Get Free Report) was the target of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 100 shares, a drop of 99.1% from the February 28th total of 11,300 shares. Currently, 0.0% of the company's shares are sold short. Based on an average daily trading volume, of 15,800 shares, the days-to-cover ratio is currently 0.0 days.

Hypera Trading Down 3.4 %

HYPMY stock traded down $0.12 during trading on Monday, reaching $3.39. 438 shares of the stock traded hands, compared to its average volume of 8,438. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.81 and a quick ratio of 1.41. The firm has a market capitalization of $2.15 billion, a PE ratio of 8.48 and a beta of 0.99. Hypera has a 52-week low of $2.64 and a 52-week high of $6.65. The business's 50 day moving average price is $3.31 and its 200-day moving average price is $3.67.

Hypera (OTCMKTS:HYPMY - Get Free Report) last released its earnings results on Thursday, March 20th. The company reported $0.02 EPS for the quarter. The company had revenue of $258.56 million during the quarter. Hypera had a return on equity of 13.18% and a net margin of 20.04%.

About Hypera

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.